医学
内科学
肿瘤科
结直肠癌
临床终点
贝伐单抗
奥沙利铂
阿替唑单抗
无容量
癌症
临床试验
化疗
免疫疗法
作者
Michael J. Overman,Greg Yothers,Samuel A. Jacobs,Hanna K. Sanoff,Deirdre Jill Cohen,Katherine A. Guthrie,N. Lynn Henry,Peter Ganz,Scott Kopetz,Peter C. Lucas,Charles D. Blanke,Norman Wolmark,Howard S. Hochster,Thomas J. George,Caio Max Sao Pedro Rocha Lima
标识
DOI:10.1200/jco.2021.39.3_suppl.tps158
摘要
TPS158 Background: Despite activity of programmed cell death-1 (PD-1) pathway inhibition in dMMR/MSI-H mCRC, approximately one-third of patients demonstrate progressive disease as best response to anti-PD1 monotherapy. Preclinical models have demonstrated synergistic interactions between FOLFOX, anti-VEGF, and anti-PD-1. We hypothesize that the dMMR/MSI-H mCRC subset may be more effectively targeted by the combination of PD-1 pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-1 therapy (atezo) alone. Methods: Initially a three-arm study, the mFOLFOX6/bev arm was closed to new enrollment on 6-4-20 due to emerging data; the redesigned COMMIT is a prospective phase III open-label trial that will randomize (1:1) mCRC dMMR/MSI-H pts (N=211) to either atezo monotherapy or mFOLFOX6/bev+atezo combination. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Primary endpoint is progression-free survival (PFS) as assessed by site investigator. Secondary endpoints include OS, objective response rate, safety profile, disease control rate, duration of response, and centrally-reviewed PFS. Health-related quality of life is an exploratory objective. Archived tumor tissue and blood samples will be collected for correlative studies. Key inclusion criteria are: mCRC without prior chemotherapy for advanced disease; dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; and measurable disease per RECIST. Support: U10CA180868, -180822, -180888, -180819, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228.
科研通智能强力驱动
Strongly Powered by AbleSci AI